Fn14-targeted BiTE and CAR-T cells demonstrate potent preclinical activity against glioblastoma
T cell-engaging therapies involving bispecific T cell engager (BiTE) and chimeric antigen receptor T (CAR-T) cells have achieved great success in the treatment of hematological tumors. However, the paucity of ideal cell surface molecules that can be targeted on glioblastoma (GBM) partially reduces t...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Taylor & Francis Group
2021-01-01
|
| Schriftenreihe: | OncoImmunology |
| Schlagworte: | |
| Online-Zugang: | http://dx.doi.org/10.1080/2162402X.2021.1983306 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|